Clinical sequencing assays aim to identify somatic mutations in cancer cells for accurate diagnosis and treatment. However, most clinical-grade implementations lack patientmatched germline DNA, and supplemental analyses are needed to infer the mutational status of variants. In addition, genomic heterogeneity confounds the ability to distinguish subclonal tumor alterations from those possibly originating from the microenvironment's nontumor component. Recent studies have shown that certain mutations identified in sequencing assays did not reflect alterations in the tumor but instead revealed alterations in infiltrating hematopoietic cells possibly from undiagnosed clonal hematopoiesis of indeterminate potential (CHIP), 1,2 an age-related expansion of hematopoietic stem cells harboring somatic mutations predominantly in DNMT3A (GenBank 1788), TET2 (GenBank 54790), and ASXL1 (GenBank 171023). Mutations in other genes associated with hematologic diseases are detected less frequently in CHIP, and when these mutations are encountered, reports have attributed them either to the tumor or to CHIP.
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We examined whether detection of these mutations might indicate the presence of other disorders. Specifically, the JAK2-V617F mutation has been directly linked to myeloproliferative neoplasms (MPNs), and detection of this mutation, along with activating exon 12 JAK2 (GenBank 3717) mutations and alterations in MPL (GenBank 4352) or CALR (GenBank 811) can establish a diagnosis of MPN. (Table) . Three patients had available specimens. To validate that JAK2 mutations existed in hematopoietic elements, we performed manual macrodissection on paraffin-embedded specimens to enrich for cancer or hematopoietic cells and sequenced these samples at high depth (>2500×) using a 49-gene panel (RainDance Technologies) on Illumina MiSeq. We identified all sites that were different from the reference using an inclusive variant caller 5 and used a Bayesian approach to detect true mutations against background error 6 in which mutations were tested in each sample against 33 previously sequenced, JAK2 wildtype samples. After correcting for multiple hypotheses using the Benjamini-Hochberg method, we generated a list of variants with a false-discovery rate less than 0.001. Clinical records and patient samples for this study were obtained under approval from Rutgers University Institutional Review Board protocol 2012002075 with written consent (4 of 8 patients) and protocol 20170001364 with waived consent (4 of 8 patients).
Results | Examination of patients' clinical histories indicated that 4 of the 8 patients with JAK2-V617F mutations detected on solid tumor sequencing had a diagnosis of MPN; 2 had polycythemia vera, 1 had essential thrombocythemia, and 1 had myelofibrosis. One additional patient had a platelet count of 529 × 10 3 /μL (to convert to cells ×10 9 per liter, multiply by 1.0) before initiating chemotherapy, whereas interpretation of the results of blood tests for the 3 other patients without a diagnosis of MPN was confounded by receipt of concurrent chemotherapy. In the validation analysis of the macrodissected specimens, 2 of the 3 patients had JAK2-V617F in lymphocyte-enriched samples at significantly higher VAFs (5.6% at 2807× and 28.1% at 3029×, respectively) than in tumor-enriched samples (3.5% at 3264× and 5.9% at 1772×, respectively) (P < .001, Fisher exact test). For these patients, tumor-specific mutations were all detected at significantly higher VAFs in tumor-enriched samples. In 1 patient, CHIP-associated mutations in U2AF1 (GenBank 7307) and TET2 were also detected at significantly higher VAFs in the lymphocyte-enriched sample. In the third patient without a prior diagnosis of MPN, JAK2-V617F was detected at a significantly higher VAF in the tumor-enriched sample (12% at 1788× vs 2.2% at 2757×). In this patient, a CHIPassociated mutation in DNMT3A was detected at a significantly higher VAF in the lymphocyte-enriched sample, suggesting that JAK2-V617F was likely present in tumor cells (Table) .
Discussion | There have been conflicting reports in the literature as to whether JAK2-V617F detected by solid tumor sequencing is associated with a mutation in the tumor or CHIP.
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Our analysis suggests that although both of these results are possible, detection of JAK2-V617F may instead be associated with a coexistent MPN. Limitations may arise in distinguishing underlying JAK2-V617F mutations from CHIP versus those from an MPN in patients receiving chemotherapy for their solid tumors. Therefore, when MPN-associated mutations are observed in solid tumor sequencing data, caution is necessary for proper patient treatment, and a hematologic workup should be considered in the appropriate clinical context. 
